Craftport Cannabis Performance dei guadagni passati
Il passato criteri di controllo 0/6
Craftport Cannabis's earnings have been declining at an average annual rate of -18.4%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 49.5% per year.
Informazioni chiave
-18.4%
Tasso di crescita degli utili
8.8%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 23.1% |
| Tasso di crescita dei ricavi | 49.5% |
| Rendimento del capitale proprio | n/a |
| Margine netto | -4,454.1% |
| Ultimo aggiornamento sui guadagni | 30 Sep 2022 |
Aggiornamenti sulle prestazioni recenti
Ripartizione dei ricavi e delle spese
Come Craftport Cannabis guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -8 | 3 | 0 |
| 30 Jun 22 | 0 | -8 | 3 | 0 |
| 31 Mar 22 | 1 | -10 | 3 | 0 |
| 31 Dec 21 | 1 | -10 | 3 | 0 |
| 30 Sep 21 | 1 | -13 | 3 | 0 |
| 30 Jun 21 | 1 | -12 | 3 | 0 |
| 31 Mar 21 | 1 | -10 | 3 | 0 |
| 31 Dec 20 | 1 | -10 | 3 | 0 |
| 30 Sep 20 | 1 | -1 | 4 | 0 |
| 30 Jun 20 | 0 | -3 | 4 | 0 |
| 31 Mar 20 | 0 | -3 | 5 | 0 |
| 31 Dec 19 | 0 | -4 | 5 | 0 |
| 30 Sep 19 | 0 | -6 | 6 | 0 |
| 30 Jun 19 | 0 | -6 | 6 | 0 |
| 31 Mar 19 | 0 | -6 | 6 | 0 |
| 31 Dec 18 | 0 | -6 | 6 | 0 |
| 30 Sep 18 | 0 | -8 | 5 | 0 |
| 30 Jun 18 | 0 | -7 | 4 | 0 |
| 31 Mar 18 | 0 | -5 | 3 | 0 |
| 31 Dec 17 | 0 | -4 | 2 | 0 |
| 30 Sep 17 | 0 | -2 | 1 | 0 |
| 30 Jun 17 | 0 | -1 | 1 | 0 |
| 31 Mar 17 | 0 | -1 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
Guadagni di qualità: CFT is currently unprofitable.
Margine di profitto in crescita: CFT is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: CFT is unprofitable, and losses have increased over the past 5 years at a rate of 18.4% per year.
Accelerare la crescita: Unable to compare CFT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: CFT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Rendimento del capitale proprio
ROE elevato: CFT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.